PLX Protalix BioTherapeutics, Inc.: Business Value to Revenue

Protalix BioTherapeutics, Inc. (PLX) - corporate logo

A stable staff of R&D specialists provides Protalix BioTherapeutics (PLX) with a technological advantage. The EV/Sales trend visualizes the market valuation of assets, where the 2532.88 mark characterizes this parameter. Current indicators are based on the expansion of the drug Elfabrio, however, geopolitical risks and sanctions complicate the supply of components from Israel, which may slow the global scaling pace of the biopharmaceutical platform.

Protalix (PLX) EV/Sales Multiple: for the period 11/23/2025 - 11/19/2026

PLX (Protalix): analytical breakdowns and indicator data

- current quotes and average value forecast:
Initial company analysis:PLX, Protalix BioTherapeutics, Inc.
Brand item of Protalix BioTherapeutics Inc.

Protalix BioTherapeutics is optimizing rare disease therapy costs through its innovative ProCellEx protein production platform. This metric correlates enterprise value (EV) with sales volume, excluding the impact of debt load. By analyzing the EV-to-revenue chart, an investor assesses the market premium paid for every dollar of revenue. This indicator's trend reflects market expectations regarding the scaling of the plant-based ecosystem, allowing for an objective assessment of the company's capital stability.